证券代码：688799 证券简称：华纳药厂 公告编号：2025-092 湖南华纳大药厂股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 12 月 26 日 14 点 30 分 召开地点：湖南省长沙市岳麓区麓天路 28 号 C7 栋公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 26 日 至2025 年 12 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年12月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-089 二、监事会会议审议情况 本次会议审议通过了如下议案： （一）审议通过《关于变更注册资本、取消监事会、调整董事会人数、修 订<公司章程>并办理工商变更登记的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 表决结果：3 票同意，0 票反对，0 票弃权。 湖南华纳大药厂股份有限公司 第四届监事会第四次会议决议公告 公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届监事会第四次会 议于 2025 年 12 月 10 日以现场结合通讯方式召开，本次会议的通知于 2025 年 11 月 30 日送达公司全体监事。会议由监事会主席马飞先生主持，应出席监事 3 人，实际出席监事 3 人。会议的召集、召开、表决程序符合相关法律、法规及《湖 南华纳大药厂股份有限公司章程》（以下简称"《公司章程》"）的相关规定，所作 决议合法有效。 2025 年 12 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-088 湖南华纳大药厂股份有限公司 第四届董事会第四次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届董事会第四次会 议于 2025 年 12 月 10 日以现场结合通讯方式召开，本次会议的通知于 2025 年 11 月 30 日送达公司全体董事。会议由董事长黄本东先生主持，应出席董事 7 人， 实际出席董事 7 人。会议的召集、召开、表决程序符合相关法律、法规及《湖南 华纳大药厂股份有限公司章程》（以下简称"《公司章程》"）的相关规定，所作决 议合法有效。 二、董事会会议审议情况 本次会议审议通过了如下议案： （一）审议通过《关于变更注册资本、取消监事会、调整董事会人数、修 订<公司章程>并办理工商变更登记的议案》 本议案中《湖南华纳大药厂股份有限公司股东会议事规则》、《湖南华纳大药 厂股份有限公司股东会网络投票实施细则》、《湖南华纳大药厂股份有限公司累积 投票制实施细则 ...

华纳药厂12月10日公告，公司近日收到国家药品监督管理局核准签发的硫酸镁钠钾口服用浓溶液《药品 注册证书》。硫酸镁钠钾口服用浓溶液适用于成人，用于任何需要清洁肠道的操作前的肠道清洁（如需 要肠道可视化的操作包括内镜、放射性检查、外科手术）。本品不用于治疗便秘。公司硫酸镁钠钾口服 用浓溶液按新注册分类化学药品4类获得药品注册证书，视同通过一致性评价。 ...

Core Viewpoint - Warner Pharmaceuticals has received approval from the National Medical Products Administration for the drug registration certificate of Formoterol Fumarate Inhalation Solution [2] Group 1 - The approval signifies a significant regulatory milestone for the company [2] - The inhalation solution is expected to enhance the company's product portfolio in respiratory therapies [2]

Group 1 - Jianbang Co., Ltd. plans to repurchase shares using self-owned funds between 15 million and 30 million yuan, with a maximum price of 38 yuan per share [1] - Yatong Precision Engineering's investment in a private equity fund has been terminated due to failure to complete the agreed investment, leading to the fund's dissolution [1] - China Storage Co., Ltd. intends to invest 1.129 billion yuan in the Sanjiang Port project, with its wholly-owned subsidiary contributing 500 million yuan to establish a project company [2] Group 2 - Guangxin Co., Ltd. plans to inject assets worth 4.383 billion yuan into its wholly-owned subsidiary, increasing its registered capital from 10 million to 20 million yuan [3] - Jiangxin Home plans to use up to 3 billion yuan of idle self-owned funds for cash management in low-risk financial products [4] - Huangshan Tourism intends to lease part of the Huangshan scenic area for 1.27 billion yuan over a 10-year period [5] Group 3 - Jilin Expressway's general manager has resigned due to work adjustments [6] - Guoyao Modern's subsidiary has received a drug registration certificate for hydromorphone hydrochloride injection, suitable for pain management [8] - Hangya Technology plans to invest up to 70 million USD to establish subsidiaries in Singapore and Malaysia [10] Group 4 - ST Sailong's subsidiary has received approval for the listing of two chemical raw materials [11] - Shanghai Pharmaceuticals' tramadol hydrochloride injection has passed the consistency evaluation for generic drugs [12] - Yubang Electric has obtained a laboratory accreditation certificate from CNAS, indicating its testing capabilities [14] Group 5 - ST Lifang's stock will be subject to delisting risk warning starting December 1 due to administrative penalties [15] - Zhejiang Longsheng is investing 200 million yuan in a private equity partnership focused on high-potential enterprises [15] - Huayang Co., Ltd.'s subsidiary has obtained safety production permits, allowing it to commence production [16] Group 6 - Xujie Electric has won a bid for a State Grid project worth 1.518 billion yuan [17] - Pinggao Electric and its subsidiaries have collectively won a State Grid project worth approximately 773 million yuan [17] - ST Lanhua's subsidiary has entered the trial production phase for a juice beverage project with a total investment of up to 65 million yuan [18] Group 7 - Huakong Saige has terminated its stock issuance plan due to various considerations [19] - Yatong Co., Ltd. plans to invest 36 million yuan to establish a joint venture in renewable energy [20] - Warner Pharmaceuticals has received a drug registration certificate for a new inhalation solution for COPD patients [21] Group 8 - Demais has raised the upper limit for its share repurchase price to 45 yuan per share [22] - China West Electric's subsidiaries have collectively won a State Grid procurement project worth approximately 2.98 billion yuan [22] - Changan Automobile's joint venture has submitted a listing application to the Hong Kong Stock Exchange [23] Group 9 - Yinlun Co., Ltd. plans to invest approximately 133 million yuan to acquire a controlling stake in Shenzhen Deep Blue Electronics [24] - Zhongfu Information intends to increase its wholly-owned subsidiary's capital by 380 million yuan [24] - Financial Street's major shareholder has reduced its stake by 0.25% [25] Group 10 - Audiwei has formally submitted an application for H-share listing [26] - Zhongcai Technology's private placement application has been accepted by the Shenzhen Stock Exchange [27] - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on semiconductor investments [28] Group 11 - Jinkai New Energy is planning to transfer 51% of its subsidiary's equity to introduce strategic investors [31] - Huafeng Technology has reduced its fundraising target for a private placement to no more than 972 million yuan [32] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan [33] Group 12 - Zhongman Petroleum's shareholders plan to reduce their holdings by up to 3% [35] - Innovation New Materials' shareholder intends to reduce their stake by up to 1% [37] - Guangdong Construction has signed a framework agreement to establish a quality testing base in Linzhi Economic Development Zone [39]

Group 1 - Warner Pharmaceuticals has received approval from the National Medical Products Administration for the drug registration certificate of Formoterol Fumarate Inhalation Solution [1] - The company's revenue composition for the year 2024 is projected to be 99.01% from pharmaceutical manufacturing and 0.99% from other businesses [1] - As of the report, Warner Pharmaceuticals has a market capitalization of 6.4 billion yuan [1]

近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的富马酸福莫特罗吸入溶液《药品注册证书》，现将相关情况 公告如下： 一、药品相关信息 1、药品名称：富马酸福莫特罗吸入溶液 证券代码：688799 证券简称：华纳药厂 公告编号：2025-087 湖南华纳大药厂股份有限公司 自愿披露关于获得药品注册证书的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三、对公司的影响及风险提示 2、剂 型：吸入制剂 8、上市许可持有人：湖南华纳大药厂股份有限公司 3、规 格：2ml 20μg（按（C₁₉H₂₄N₂O₄）₂·C₄H₄O₄计） 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范 要求方可生产销售。 二、药品的相关情况 富马酸福莫特罗吸入溶液用于慢性阻塞性肺部疾病（COPD）患者支气管狭 窄的维持治疗，包括慢性支气管炎和肺气肿，每日两次 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration for the drug registration certificate of Formoterol Fumarate Inhalation Solution, which is intended for the maintenance treatment of bronchial constriction in patients with Chronic Obstructive Pulmonary Disease (COPD) [1] Group 1 - The Formoterol Fumarate Inhalation Solution is specifically used for patients with COPD, including chronic bronchitis and emphysema [1] - The medication is to be administered twice daily (morning and evening) and can be used for long-term treatment [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration for the drug registration certificate of Formoterol Fumarate Inhalation Solution, which is intended for the maintenance treatment of bronchial constriction in patients with Chronic Obstructive Pulmonary Disease (COPD) [1] Group 1 - The Formoterol Fumarate Inhalation Solution is specifically used for patients with COPD, including chronic bronchitis and emphysema [1] - The medication is to be administered twice daily, in the morning and evening, and can be used for long-term treatment [1]